Skip to content
MarketScale
‹ Back to IndustriesSciences

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics has hired Neil Anderson, Ph.D. as the Chief Revenue Officer to spearhead the commercialization of its nanoimprint flat optics platform. The platform is intended for use in AI datacenters, augmented reality (AR), and life sciences applications. Anderson's experience in photonics is expected to aid Myrias Optics in expanding its market presence in these sectors.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By MarketScale Newsroom · Myrias OpticsMetaopticsFlat OpticsPhotonics
Share
Learn this in 60 seconds

Key facts, context, and what it means, in one minute.

:60
0:001:00
Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Key takeaways

01

Myrias Optics appointed Neil Anderson, Ph.D. as CRO to lead the commercialization of its technology.

02

The company focuses on nanoimprint flat optics for AI datacenters, AR, and life sciences.

03

Neil Anderson brings extensive photonics expertise to support Myrias Optics' growth.

Myrias Optics named Neil Anderson, Ph.D. as its new Chief Revenue Officer on July 22, bringing a 15-year track record in photonics commercialization to a company positioning its wafer-level flat optics platform for volume production across AI infrastructure, augmented reality, and life sciences. The Amherst, Massachusetts company announced the hire via PR Newswire, citing Anderson's history of converting deep-tech optical products into scalable, market-leading businesses at Gooch & Housego, quantum startup Infleqtion, and IDEX Corporation.

Anderson's scope at Myrias covers global sales, business development, marketing, strategic partnerships, and commercial operations, essentially every function between the laboratory and a signed purchase order. The appointment signals that Myrias is moving from technology validation into aggressive market capture, a shift that will matter to procurement and engineering teams evaluating optical component suppliers in several fast-moving verticals.

A manufacturing platform built for volume, not just prototypes

Myrias' central asset is its all-inorganic nanoimprint lithography process, which produces metaoptics and diffractive optical elements at the wafer level. According to the company, the platform combines industry-leading material performance with strong yield characteristics and a clear path to production-scale deployment, attributes that matter directly to supply chain leaders trying to qualify new optical components without absorbing yield-driven cost surprises.

Conventional optics manufacturing often struggles to keep pace with the volume demands of AI datacenter buildouts and the tight form-factor requirements of AR headsets. Wafer-level production addresses both constraints by treating optical elements more like semiconductor components, enabling tighter tolerances and higher throughput than traditional glass-grinding or injection-molding approaches. Myrias' inorganic material choice also offers thermal and environmental durability advantages relevant to datacenter and industrial deployments.

Wafer-level flat optics production is increasingly a sourcing variable, not just a technology curiosity, and Myrias is now staffing for volume.

The company's commercial traction appears to back that framing. A separate PR Newswire release from Myrias noted more than 25 customer engagements across AR, datacom, and consumer electronics, a pipeline that suggests enterprise buyers are already evaluating the platform for near-term programs, not just long-range roadmap conversations.

Anderson's background spans the markets Myrias is targeting

Anderson holds a Ph.D. in optical science and engineering from the University of Rochester's Institute of Optics and a master's degree in physics, according to PR Newswire. That technical grounding has been central to his career model: building trust with engineering and procurement counterparts at complex enterprise accounts before converting that credibility into commercial wins.

At Gooch & Housego, a precision photonics manufacturer serving aerospace, defense, and industrial markets, Anderson led commercial teams responsible for global growth. His time at Infleqtion, a quantum technology startup, added experience translating early-stage science into structured go-to-market programs. At IDEX Corporation, a diversified industrial manufacturer with significant optical and photonic business units, he managed enterprise partnerships with Fortune 1000 accounts across semiconductor, medical diagnostics, and datacom verticals, according to both the Myrias website and the PR Newswire announcement.

That cross-vertical résumé maps almost exactly onto the end markets Myrias is chasing: AI datacenters need high-volume optical interconnect components, AR device makers need manufacturable waveguide solutions, and life sciences customers need precision imaging optics that can pass regulatory scrutiny. Anderson has sold into all three.

What the hire means for teams evaluating optical component suppliers

CEO John Fijol, in remarks reported by both Myrias and PR Newswire, framed the appointment around scale: Anderson's ability to build enduring partnerships with global enterprise companies will be critical as Myrias expands manufacturing capacity. That language matters to procurement directors assessing supplier readiness. A company adding CRO-level commercial infrastructure is typically preparing to support larger program commitments, longer-term supply agreements, qualified-supplier status processes, and dedicated account management.

Anderson, in his own remarks published in the same release, described Myrias' manufacturing approach as redefining how AR waveguide and meta optics are produced at scale, and pointed to the company's ambition to establish market leadership in high-volume flat optics. For engineering and supply chain teams at AR hardware companies or datacenter optical module vendors, that positioning is worth tracking now, before design-win windows close on next-generation platform programs.

Myrias currently operates from Amherst, Massachusetts. With more than 25 active customer engagements already confirmed across key verticals, the CRO hire is the next step in converting that pipeline into production-stage contracts.

Featured companies

About the author

MarketScale Newsroom
MarketScale NewsroomEditorial Team, MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

MarketScale Newsroom
MarketScale Newsroom

Editorial Team

MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

NA
Neil Anderson

CRO

Myrias Optics

Neil Anderson, Ph.D., joins Myrias Optics as Chief Revenue Officer to drive the commercialization of its nanoimprint flat optics platform across AI datacenters, augmented reality, and life sciences.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512